Jordyn Sava is an editor for Targeted Oncology.
Primary Goal Met With Praluzatamab Ravtansine in HR-Positive, HER2-Negative Breast Cancer
July 11th 2022Praluzatamab ravtansine achieved confirmed overall response rate in patients with advanced hormone receptor–positive, HER2-negative breast cancer, meeting the primary end point of the phase 2 CTMX-2009-002 trial.
FDA Halts Phase 1/2 Trial Evaluating NUV-422 in Solid Tumors
June 28th 2022A partial clinical hold has been placed by the FDA on the phase 1/2 NUV-422-02 trial examining NUV-422 in solid tumors, including high grade glioma, hormone receptor–positive advanced breast cancer, and metastatic castration-resistant prostate cancer.
Recommended Phase 2 Dose of Tebentafusp Shows Promise in Metastatic Uveal Melanoma
June 17th 2022A manageable side-effect profile, signal of efficacy, and 36% increase in the recommended phase 2 dose (RP2D) was seen with a step-up dosing regimen of tebentafusp in patients with metastatic uveal melanoma.
Investigation of Novel CAR T Product, MB-106, in Various R/R B-Cell Malignancies
June 16th 2022In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.